GSK gets EU regulator backing for expanded use of RSV vaccine
Dec 12 (Reuters) - GSK GSK.L said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader use.
The British drugmaker said a formal and final approval to market the vaccine for this expanded indication in the European Union was expected in February next year, with the vaccine competing against Pfizer's PFE.N Abrysvo and Moderna's MRNA.O mResvia.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Subhranshu Sahu)
((pushkala.a@thomsonreuters.com; X and LinkedIn: @pullthekart;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments